GOVX Stock Summary and Trading Ideas (Geovax Labs | NASDAQ:GOVX)

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Geovax Labs trades on the NASDAQ stock market under the symbol GOVX.

As of December 22, 2025, GOVX stock price climbed to $0.17 with 7,542,226 million shares trading.

GOVX has a beta of 1.02, meaning it tends to be more sensitive to market movements. GOVX has a correlation of 0.02 to the broad based SPY ETF.

GOVX has a market cap of $5.18 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, GOVX traded as high as $20.85 and as low as $.12.

The top ETF exchange traded funds that GOVX belongs to (by Net Assets): VXF.

GOVX has underperformed the market in the last year with a price return of -92.6% while the SPY ETF gained +18.8%. GOVX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -73.4% and -54.3%, respectively, while the SPY returned +3.5% and +0.2%, respectively.

GOVX support price is $.15 and resistance is $.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GOVX shares will trade within this expected range on the day.